LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

patients, chemotherapy, cancer, agent, agents, gastric, study, treatment, article, irinotecan, exposure, platinum, survival, advanced, agc, google, scholar, analysis, fluorouracil, class, oncol, taxanes, line, results, months, firstline, phase, multivariate, versus, clin, cisplatin, analyses, table, pubmed, progression, trial, clinical, iii, oncology, regimens, japan, tvc, disease, cas, median, classes, therapy, randomized, received, patient,

Topics {✒️}

masahiro tajika & hiroki kawai nccn practice guidelines capecitabine/cisplatin versus 5-fluorouracil/cisplatin advanced gastric cancer inoperable gastric cancer large sample size false-positive associations due phase iii trial privacy choices/manage cookies metastatic gastric cancer phase iii study recurrent gastric cancer metastatic colorectal cancer advanced esophagogastric cancer gastric cancer patients v325 study group retrospective cohort study marginal structural models time-varying covariate retrospective nature statistically significant improvement false-positive association article shitara european economic area related subjects sufficient bone marrow checking medical records confounding variables considered arbeitsgemeinschaft internistische onkologie detailed clinical information versus weekly paclitaxel gastric cancer gastric cancer 14 multivariate cox model main content log conditions privacy policy simple prognostic factor stata corp lp lead-time bias clinical practice 5-fluorouracil continuous infusion backward stepwise progression gathering detailed information cisplatin versus uracil accepting optional cookies clinical oncology combination chemotherapy consisting triplet combination chemotherapy post-disease progression written informed consent

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
         description:Although fluoropyrimidines, platinum agents, taxanes, and irinotecan are used in the treatment of advanced gastric cancer (AGC), it remains unclear whether these agents in any line of chemotherapy are associated with overall survival (OS) in these patients. We retrospectively analyzed 704 patients with AGC. To avoid possible lead-time bias, we applied time-varying covariate analysis for chemotherapy with four agents in any line. Median OS was 12.3 months. The frequency of exposure to each agent class during all lines of treatment was 92.6% for FU (5-fluorouracil or oral fluoropyrimidine), 48.2% for platinum agents, 65.1% for taxanes, and 39.1% for irinotecan. According to a multivariate Cox model with exposure to each agent class as a time-varying covariate, the hazard ratios (HRs) of death were 0.41 (95% confidence interval [CI], 0.27–0.57; p < 0.001) for FU, 0.71 (95% CI, 0.58–0.84; p < 0.001) for platinum agents, 0.51 (95% CI, 0.41–0.63; p < 0.001) for taxanes, and 0.53 (95% CI, 0.43–0.65; p < 0.001) for irinotecan. Although other agents were used in 18.6% of the patients, they did not affect survival. Each of the four agent classes (FU, platinum agents, taxanes, and irinotecan) appears to be independently associated with improved OS in patients with AGC regardless of timing. This result suggests the importance of developing strategies which make these active agents available to all patients with AGC to prolong OS.
         datePublished:2011-02-23T00:00:00Z
         dateModified:2011-02-23T00:00:00Z
         pageStart:155
         pageEnd:160
         sameAs:https://doi.org/10.1007/s10120-011-0019-3
         keywords:
            Gastric cancer
            Chemotherapy
            Fluorouracil
            Platinum agent
            Paclitaxel
            Irinotecan
            Surgical Oncology
            Oncology
            Abdominal Surgery
            Gastroenterology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig3_HTML.gif
         isPartOf:
            name:Gastric Cancer
            issn:
               1436-3305
               1436-3291
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Japan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Kohei Shitara
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Keitaro Matsuo
               affiliation:
                     name:Aichi Cancer Center Research Institute
                     address:
                        name:Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ayako Mizota
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chihiro Kondo
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Motoo Nomura
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daisuke Takahari
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tomoya Yokota
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Takashi Ura
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Seiji Ito
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akira Sawaki
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masahiro Tajika
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hiroki Kawai
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kei Muro
               affiliation:
                     name:Aichi Cancer Center Hospital
                     address:
                        name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer
      description:Although fluoropyrimidines, platinum agents, taxanes, and irinotecan are used in the treatment of advanced gastric cancer (AGC), it remains unclear whether these agents in any line of chemotherapy are associated with overall survival (OS) in these patients. We retrospectively analyzed 704 patients with AGC. To avoid possible lead-time bias, we applied time-varying covariate analysis for chemotherapy with four agents in any line. Median OS was 12.3 months. The frequency of exposure to each agent class during all lines of treatment was 92.6% for FU (5-fluorouracil or oral fluoropyrimidine), 48.2% for platinum agents, 65.1% for taxanes, and 39.1% for irinotecan. According to a multivariate Cox model with exposure to each agent class as a time-varying covariate, the hazard ratios (HRs) of death were 0.41 (95% confidence interval [CI], 0.27–0.57; p < 0.001) for FU, 0.71 (95% CI, 0.58–0.84; p < 0.001) for platinum agents, 0.51 (95% CI, 0.41–0.63; p < 0.001) for taxanes, and 0.53 (95% CI, 0.43–0.65; p < 0.001) for irinotecan. Although other agents were used in 18.6% of the patients, they did not affect survival. Each of the four agent classes (FU, platinum agents, taxanes, and irinotecan) appears to be independently associated with improved OS in patients with AGC regardless of timing. This result suggests the importance of developing strategies which make these active agents available to all patients with AGC to prolong OS.
      datePublished:2011-02-23T00:00:00Z
      dateModified:2011-02-23T00:00:00Z
      pageStart:155
      pageEnd:160
      sameAs:https://doi.org/10.1007/s10120-011-0019-3
      keywords:
         Gastric cancer
         Chemotherapy
         Fluorouracil
         Platinum agent
         Paclitaxel
         Irinotecan
         Surgical Oncology
         Oncology
         Abdominal Surgery
         Gastroenterology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10120-011-0019-3/MediaObjects/10120_2011_19_Fig3_HTML.gif
      isPartOf:
         name:Gastric Cancer
         issn:
            1436-3305
            1436-3291
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Japan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Kohei Shitara
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Keitaro Matsuo
            affiliation:
                  name:Aichi Cancer Center Research Institute
                  address:
                     name:Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ayako Mizota
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chihiro Kondo
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Motoo Nomura
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daisuke Takahari
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tomoya Yokota
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Takashi Ura
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Seiji Ito
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akira Sawaki
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masahiro Tajika
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hiroki Kawai
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kei Muro
            affiliation:
                  name:Aichi Cancer Center Hospital
                  address:
                     name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Gastric Cancer
      issn:
         1436-3305
         1436-3291
      volumeNumber:14
Organization:
      name:Springer Japan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Research Institute
      address:
         name:Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
      name:Aichi Cancer Center Hospital
      address:
         name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Kohei Shitara
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Keitaro Matsuo
      affiliation:
            name:Aichi Cancer Center Research Institute
            address:
               name:Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Ayako Mizota
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Chihiro Kondo
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Motoo Nomura
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Daisuke Takahari
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Tomoya Yokota
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Takashi Ura
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Seiji Ito
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Akira Sawaki
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Masahiro Tajika
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Hiroki Kawai
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Kei Muro
      affiliation:
            name:Aichi Cancer Center Hospital
            address:
               name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
      name:Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

External Links {🔗}(90)

• How much profit does https://www.springernature.com/gp/authors generate?
• Earnings of https://link.springernature.com/home/
• Learn about the earnings of https://order.springer.com/public/cart
• Learn how profitable https://www.editorialmanager.com/gcan is on a monthly basis
• Profit of https://beta.springernature.com/pre-submission?journalId=10120
• What's http://www-dep.iarc.fr/CancerMondial.htm's gross income?
• Earnings of https://doi.org/10.1200%2FJCO.2006.06.8429
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17075117 generate?
• http://scholar.google.com/scholar_lookup?&title=Phase%20III%20study%20of%20docetaxel%20and%20cisplatin%20plus%20fluorouracil%20compared%20with%20cisplatin%20and%20fluorouracil%20as%20first-line%20therapy%20for%20advanced%20gastric%20cancer%3A%20a%20report%20of%20the%20V325%20Study%20Group&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2006.06.8429&volume=24&pages=4991-4997&publication_year=2006&author=Cutsem%2CE&author=Moiseyenko%2CVM&author=Tjulandin%2CS&author=Majlis%2CA&author=Constenla%2CM&author=Boni%2CC's total income per month
• What is the earnings of https://doi.org/10.1056%2FNEJMoa073149?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18172173 gross monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Capecitabine%20and%20oxaliplatin%20for%20advanced%20esophagogastric%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa073149&volume=358&pages=36-46&publication_year=2008&author=Cunningham%2CD&author=Starling%2CN&author=Rao%2CS&author=Iveson%2CT&author=Nicolson%2CM&author=Coxon%2CF generate monthly?
• What are the total earnings of https://doi.org/10.1016%2FS1470-2045%2808%2970035-4?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18282805 bring in?
• How much income does http://scholar.google.com/scholar_lookup?&title=S-1%20plus%20cisplatin%20versus%20S-1%20alone%20for%20first-line%20treatment%20of%20advanced%20gastric%20cancer%20%28SPIRITS%20trial%29%3A%20a%20phase%20III%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2808%2970035-4&volume=9&pages=215-221&publication_year=2008&author=Koizumi%2CW&author=Narahara%2CH&author=Hara%2CT&author=Takagane%2CA&author=Akiya%2CT&author=Takagi%2CM have?
• Find out how much https://doi.org/10.1093%2Fannonc%2Fmdn717 earns monthly
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19153121 generate monthly?
• What's http://scholar.google.com/scholar_lookup?&title=Capecitabine%2Fcisplatin%20versus%205-fluorouracil%2Fcisplatin%20as%20first-line%20therapy%20in%20patients%20with%20advanced%20gastric%20cancer%3A%20a%20randomised%20phase%20III%20noninferiority%20trial&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdn717&volume=20&pages=666-673&publication_year=2009&author=Kang%2CYK&author=Kang%2CWK&author=Shin%2CDB&author=Chen%2CJ&author=Xiong%2CJ&author=Wang%2CJ's gross income?
• Learn about the earnings of https://doi.org/10.1200%2FJCO.2009.25.4706
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20159816 pull in?
• How much does http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20III%20comparison%20of%20cisplatin%2Fs-1%20with%20cisplatin%2Finfusional%20fluorouracil%20in%20advanced%20gastric%20or%20gastroesophageal%20adenocarcinoma%20study%3A%20the%20FLAGS%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2009.25.4706&volume=28&pages=1547-1553&publication_year=2010&author=Ajani%2CJA&author=Rodriguez%2CW&author=Bodoky%2CG&author=Moiseyenko%2CV&author=Lichinitser%2CM&author=Gorbunova%2CV bring in each month?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20II%20study%20of%20best-available%205-fluorouracil%20%285-FU%29%20versus%20weekly%20paclitaxel%20in%20gastric%20cancer%20%28GC%29%20with%20peritoneal%20metastasis%20%28PM%29%20refractory%20to%205-FU-containing%20regimens%20%28JCOG0407%29&journal=J%20Clin%20Oncol&volume=28&publication_year=2010&author=Takiuchi%2CH&author=Fukuda%2CH&author=Boku%2CN&author=Shimada%2CY&author=Nasu%2CJ&author=Hamamoto%2CY is on a monthly basis
• Income figures for http://scholar.google.com/scholar_lookup?&title=Survival%20prolongation%20after%20treatment%20failure%20in%20patients%20with%20advanced%20gastric%20cancer%20%28AGC%29%3A%20results%20from%20combined%20analysis%20of%20JCOG9205%20and%20JCOG9912&journal=J%20Clin%20Oncol&volume=28&publication_year=2010&author=Takashima%2CA&author=Boku%2CN&author=Kato%2CK&author=Mizusawa%2CJ&author=Nakamura%2CK&author=Fukuda%2CH
• How much revenue does https://doi.org/10.1016%2FS1470-2045%2809%2970259-1 bring in?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19818685's total income per month
• Find out how much http://scholar.google.com/scholar_lookup?&title=Gastrointestinal%20Oncology%20Study%20Group%20of%20the%20Japan%20Clinical%20Oncology%20Group.%20Fluorouracil%20versus%20combination%20of%20irinotecan%20plus%20cisplatin%20versus%20S-1%20in%20metastatic%20gastric%20cancer%3A%20a%20randomised%20phase%203%20study&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2809%2970259-1&volume=10&pages=1063-1069&publication_year=2009&author=Boku%2CN&author=Yamamoto%2CS&author=Fukuda%2CH&author=Shirao%2CK&author=Doi%2CT&author=Sawaki%2CA earns monthly
• http://scholar.google.com/scholar_lookup?&title=Irinotecan%20plus%20S-1%20%28IRIS%29%20versus%20S-1%20alone%20as%20first%20line%20treatment%20for%20advanced%20gastric%20cancer%3A%20preliminary%20results%20of%20a%20randomized%20phase%20III%20study%20%28GC0301%2FTOP-002%29&journal=J%20Clin%20Oncol&volume=25&publication_year=2007&author=Chin%2CK&author=Iishi%2CH&author=Imamura%2CH&author=Kobayashi%2CO&author=Imamoto%2CH&author=Esaki%2CT's revenue stream
• What's the financial outcome of https://doi.org/10.1093%2Fannonc%2Fmdn166?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18558665 make?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20study%20comparing%20irinotecan%20combined%20with%205-fluorouracil%20and%20folinic%20acid%20to%20cisplatin%20combined%20with%205-fluorouracil%20in%20chemotherapy%20naive%20patients%20with%20advanced%20adenocarcinoma%20of%20the%20stomach%20or%20esophagogastric%20junction&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdn166&volume=19&pages=1450-1457&publication_year=2008&author=Dank%2CM&author=Zaluski%2CJ&author=Barone%2CC&author=Valvere%2CV&author=Yalcin%2CS&author=Peschel%2CC?
• What's the profit of https://doi.org/10.1200%2FJCO.2008.21.7695?
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Irinotecan%20versus%20best%20supportive%20care%20%28BSC%29%20as%20second-line%20therapy%20in%20gastric%20cancer%3A%20a%20randomized%20phase%20III%20study%20of%20the%20Arbeitsgemeinschaft%20Internistische%20Onkologie%20%28AIO%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.21.7695&volume=27&publication_year=2009&author=Thuss-Patience%2CPC&author=Kretzschmar%2CA&author=Deist%2CT&author=Hinke%2CA&author=Bichev%2CD&author=Lebedinzew%2CB?
• How much does https://doi.org/10.1200%2FJCO.2003.04.130 net monthly?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12506170
• http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20trial%20of%20fluorouracil%20alone%20versus%20fluorouracil%20plus%20cisplatin%20versus%20uracil%20and%20tegafur%20plus%20mitomycin%20in%20patients%20with%20unresectable%2C%20advanced%20gastric%20cancer%3A%20the%20Japan%20Clinical%20Oncology%20Group%20Study%20%28JCOG9205%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2003.04.130&volume=21&pages=54-59&publication_year=2003&author=Ohtsu%2CA&author=Shimada%2CY&author=Shirao%2CK&author=Boku%2CN&author=Hyodo%2CI&author=Saito%2CH income
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Randomized%20phase%20III%20study%20of%205-fluorouracil%20continuous%20infusion%20%285FUci%29%20versus%20methotrexate%20and%205-FU%20sequential%20therapy%20%28MF%29%20in%20gastric%20cancer%20with%20peritoneal%20metastasis%20%28JCOG0106%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.21.7695&volume=27&publication_year=2009&author=Shirao%2CK&author=Boku%2CN&author=Yamada%2CY&author=Yamaguchi%2CK&author=Doi%2CT&author=Takiuchi%2CH?
• How much money does https://doi.org/10.1200%2FJCO.2005.05.0245 make?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16782930
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Chemotherapy%20in%20advanced%20gastric%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20based%20on%20aggregate%20data&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2005.05.0245&volume=24&pages=2903-2909&publication_year=2006&author=Wagner%2CAD&author=Grothe%2CW&author=Haerting%2CJ&author=Kleber%2CG&author=Grothey%2CA&author=Fleig%2CWE?
• How much does https://doi.org/10.1200%2FJCO.2004.11.037 net monthly?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15051767's revenue stream
• Profit of http://scholar.google.com/scholar_lookup?&title=Survival%20of%20patients%20with%20advanced%20colorectal%20cancer%20improves%20with%20the%20availability%20of%20fluorouracil-leucovorin%2C%20irinotecan%2C%20and%20oxaliplatin%20in%20the%20course%20of%20treatment&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2004.11.037&volume=22&pages=1209-1214&publication_year=2004&author=Grothey%2CA&author=Sargent%2CD&author=Goldberg%2CRM&author=Schmoll%2CHJ
• Profit of http://scholar.google.com/scholar_lookup?&title=Analysis%20of%20survival%20with%20modified%20docetaxel%2C%20cisplatin%2C%20fluorouracil%20%28mDCF%29%2C%20and%20bevacizumab%20%28BEV%29%20in%20patients%20with%20metastatic%20gastroesophageal%20%28GE%29%20adenocarcinoma%3A%20results%20of%20a%20phase%20II%20clinical%20trial%20%282009%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.21.7695&volume=27&publication_year=2009&author=Kelsen%2CD&author=Jhawer%2CM&author=Ilson%2CD&author=Tse%2CA&author=Randazzo%2CJ&author=Robinson%2CE
• Earnings of https://doi.org/10.1198%2F016214501753168154
• http://scholar.google.com/scholar_lookup?&title=Marginal%20structural%20models%20to%20estimate%20the%20joint%20effect%20of%20non-randomized%20treatments&journal=J%20Am%20Stat%20Assoc&doi=10.1198%2F016214501753168154&volume=96&pages=440-448&publication_year=2001&author=Hern%C3%A1n%2CMA&author=Brumback%2CB&author=Robins%2CJM's total income per month
• https://citation-needed.springer.com/v2/references/10.1007/s10120-011-0019-3?format=refman&flavour=references's total income per month
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kohei%20Shitara gross monthly?
• Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kohei%20Shitara%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Keitaro%20Matsuo?
• See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Keitaro%20Matsuo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
• What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ayako%20Mizota?
• What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ayako%20Mizota%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chihiro%20Kondo's revenue stream
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chihiro%20Kondo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Motoo%20Nomura bring in each month?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Motoo%20Nomura%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Daisuke%20Takahari each month?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Daisuke%20Takahari%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tomoya%20Yokota's gross income?
• Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tomoya%20Yokota%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Takashi%20Ura have monthly?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Takashi%20Ura%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Seiji%20Ito make?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Seiji%20Ito%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
• Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Akira%20Sawaki
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Akira%20Sawaki%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masahiro%20Tajika make?
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masahiro%20Tajika%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hiroki%20Kawai?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hiroki%20Kawai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en produce monthly?
• Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kei%20Muro
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kei%20Muro%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What are the total earnings of https://s100.copyright.com/AppDispatchServlet?title=Association%20of%20fluoropyrimidines%2C%20platinum%20agents%2C%20taxanes%2C%20and%20irinotecan%20in%20any%20line%20of%20chemotherapy%20with%20survival%20in%20patients%20with%20advanced%20gastric%20cancer&author=Kohei%20Shitara%20et%20al&contentID=10.1007%2Fs10120-011-0019-3©right=The%20International%20Gastric%20Cancer%20Association%20and%20The%20Japanese%20Gastric%20Cancer%20Association&publication=1436-3291&publicationDate=2011-02-23&publisherName=SpringerNature&orderBeanReset=true?
• How much does https://citation-needed.springer.com/v2/references/10.1007/s10120-011-0019-3?format=refman&flavour=citation make?
• How much profit does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral generate?
• Financial intake of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• What's the financial gain of https://www.springernature.com/gp/products?
• Income figures for https://www.springernature.com/gp/librarians
• Get to know https://www.springernature.com/gp/societies's earnings
• https://www.springernature.com/gp/partners income
• How much income is https://www.springer.com/ earning monthly?
• How much does https://www.nature.com/ rake in every month?
• How much revenue does https://www.biomedcentral.com/ generate?
• Get to know https://www.palgrave.com/'s earnings
• Earnings of https://www.apress.com/
• Monthly income for https://www.springernature.com/gp/legal/ccpa
• Discover the revenue of https://www.springernature.com/gp/info/accessibility
• How much does https://support.springernature.com/en/support/home rake in every month?
• Learn about the earnings of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
• How much does https://www.springernature.com/ pull in?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref